Compare Stocks: DSGN, QURE, ZLAB, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$31.12 -7.1%	$38.88	$22.10 ▼ $45.14	$2.63B	0.84	1.34 million shs	4.24 million shs
DSGN Design Therapeutics	$12.36 -6.1%	$13.82	$5.28 ▼ $17.25	$773.51M	1.66	770,108 shs	738,274 shs
QURE uniQure	$42.76 -5.6%	$44.64	$8.73 ▼ $71.50	$3.14B	0.94	1.14 million shs	1.15 million shs
ZLAB Zai Lab	$26.44 +0.1%	$23.61	$15.96 ▼ $34.72	$3.01B	0.83	860,770 shs	791,635 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-7.13%	-19.61%	-23.29%	-8.71%	+28.44%
DSGN Design Therapeutics	-6.08%	-1.20%	-18.84%	-8.04%	+105.32%
QURE uniQure	-5.57%	+0.64%	-9.90%	-12.91%	+213.03%
ZLAB Zai Lab	+0.11%	+7.17%	+3.12%	+42.76%	-17.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$31.12 -7.1%	$38.88	$22.10 ▼ $45.14	$2.63B	0.84	1.34 million shs	4.24 million shs
DSGN Design Therapeutics	$12.36 -6.1%	$13.82	$5.28 ▼ $17.25	$773.51M	1.66	770,108 shs	738,274 shs
QURE uniQure	$42.76 -5.6%	$44.64	$8.73 ▼ $71.50	$3.14B	0.94	1.14 million shs	1.15 million shs
ZLAB Zai Lab	$26.44 +0.1%	$23.61	$15.96 ▼ $34.72	$3.01B	0.83	860,770 shs	791,635 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-7.13%	-19.61%	-23.29%	-8.71%	+28.44%
DSGN Design Therapeutics	-6.08%	-1.20%	-18.84%	-8.04%	+105.32%
QURE uniQure	-5.57%	+0.64%	-9.90%	-12.91%	+213.03%
ZLAB Zai Lab	+0.11%	+7.17%	+3.12%	+42.76%	-17.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.86	Moderate Buy	$61.92	98.98% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	33.50% Upside
QURE uniQure	2.76	Moderate Buy	$65.00	52.01% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	40.89% Upside

Current Analyst Ratings Breakdown

Latest DSGN, QURE, ZLAB, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CLDX Celldex Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$70.00 ➝ $88.00
9/23/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $57.00
9/22/2026	CLDX Celldex Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$68.00
9/22/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $64.00
9/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$61.00 ➝ $72.00
9/21/2026	QURE uniQure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/10/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $50.00
9/2/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform
8/7/2026	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $45.00
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$158K	15,467.43	N/A	N/A	$7.93 per share	3.92
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
QURE uniQure	$16.10M	184.24	N/A	N/A	$3.19 per share	13.40
ZLAB Zai Lab	$460.16M	6.54	N/A	N/A	$6.39 per share	4.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest DSGN, QURE, ZLAB, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million
6/30/2026	Q2 2026	ZLAB Zai Lab	N/A	-$0.50	N/A	-$0.50	N/A	$106.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	11.82	11.82
DSGN Design Therapeutics	N/A	18.86	18.86
QURE uniQure	0.15	10.01	10.01
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DSGN Design Therapeutics	56.64%
QURE uniQure	78.83%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	5.20%
DSGN Design Therapeutics	17.10%
QURE uniQure	4.65%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

DSGN, QURE, ZLAB, and CLDX Headlines

Recent News About These Companies

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Analysts

September 23 at 2:15 AM | americanbankingnews.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages

September 23 at 2:13 AM | marketbeat.com

Zai Lab Limited (ZLAB)

September 11, 2026 | finance.yahoo.com

Seven Fleet Capital Management LP Acquires 58,158 Shares of Zai Lab Limited Unsponsored ADR $ZLAB

September 5, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Down 4.6% - Here's What Happened

September 4, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Trading Up 6.9% - Still a Buy?

September 2, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR $ZLAB Stock Position Boosted by Headlands Technologies LLC

September 1, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26, 2026 | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 3, 2026 | finance.yahoo.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, QURE, ZLAB, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$31.12 -2.39 (-7.13%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$30.98 -0.15 (-0.47%)

As of 07:41 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Design Therapeutics NASDAQ:DSGN

$12.36 -0.80 (-6.08%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.35 -0.01 (-0.06%)

As of 07:22 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

uniQure NASDAQ:QURE

$42.76 -2.52 (-5.57%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$42.78 +0.02 (+0.04%)

As of 07:43 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Zai Lab NASDAQ:ZLAB

$26.44 +0.03 (+0.11%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$25.45 -0.99 (-3.73%)

As of 07:35 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, QURE, ZLAB, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, QURE, ZLAB, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, QURE, ZLAB, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, QURE, ZLAB, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Design Therapeutics NASDAQ:DSGN

uniQure NASDAQ:QURE

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DSGN, QURE, ZLAB, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DSGN, QURE, ZLAB, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DSGN, QURE, ZLAB, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, QURE, ZLAB, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Design Therapeutics NASDAQ:DSGN

uniQure NASDAQ:QURE

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools